TSC2 and neoplasm: Everolimus treatment (10 mg/kg i.p.daily for 2 weeks) of mice harbouring shRNA-Tsc2/Cdkn2a∆/∆ allograft tumours blocked tumour growth and tumours regressed after cessation of treatment but re-grew after ~3 months (Fig. 8h).